Posting of Annual Report and Notice of AGM

RNS Number : 0765X

ReNeuron Group plc

26 August 2015

 



26 August 2015                                                                                                                     AIM: RENE

ReNeuron Group plc

("ReNeuron" or the "Company")

Posting of Annual Report and Accounts

 and Notice of AGM

Guildford, UK, 26 August 2015: ReNeuron Group plc, a leading UK-based stem cell therapy company, announces that its Annual Report and Accounts for the year ended 31 March 2015 and the Notice of the 2015 Annual General Meeting ("AGM") have been sent to shareholders and are also available on the Company's website at www.reneuron.com.

ReNeuron's AGM will be held at 10.30am on Thursday 24 September 2015 at the offices of Covington & Burling LLP, 265 Strand, London, WC2R 1BH.

Enquiries:

ReNeuron                                                                                                           [phone]

Olav Hellebø, Chief Executive Officer

Michael Hunt, Chief Financial Officer

Cenkos Securities                                                                                            [phone]

Stephen Keys, Dr Christopher Golden (NOMAD and Broker)

Russell Kerr (Sales)

Buchanan                                                                                                            [phone]

Mark Court, Sophie Cowles, Stephanie Watson

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development business.  Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  The Company's therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for the blindness-causing disease, retinitis pigmentosa, is about to enter the clinic in the US.   

ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting a range of cancers.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.

 

END

 

 

MSCPAMFTMBJTBJA